amantadine has been researched along with Amyotrophic Lateral Sclerosis in 7 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to develop and analyse poly(DL-lactic acid)-methacrylic acid nanospheres bound to the chelating ligand diethylenetriaminepentaacetic acid (DTPA) for the targeted delivery of amantadine in Amyotrophic Lateral Sclerosis (ALS)." | 7.88 | Targeted Delivery of Amantadine-loaded Methacrylate Nanosphere-ligands for the Potential Treatment of Amyotrophic Lateral Sclerosis. ( Choonara, YE; Du Toit, LC; Govender, M; Indermun, S; Kumar, P; Mazibuko, Z; Modi, G; Naidoo, D; Pillay, V, 2018) |
| "This study aimed to develop and analyse poly(DL-lactic acid)-methacrylic acid nanospheres bound to the chelating ligand diethylenetriaminepentaacetic acid (DTPA) for the targeted delivery of amantadine in Amyotrophic Lateral Sclerosis (ALS)." | 3.88 | Targeted Delivery of Amantadine-loaded Methacrylate Nanosphere-ligands for the Potential Treatment of Amyotrophic Lateral Sclerosis. ( Choonara, YE; Du Toit, LC; Govender, M; Indermun, S; Kumar, P; Mazibuko, Z; Modi, G; Naidoo, D; Pillay, V, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Lapshina, MA | 1 |
| Shevtsova, EF | 1 |
| Grigoriev, VV | 1 |
| Aksinenko, AY | 1 |
| Ustyugov, AA | 1 |
| Steinberg, DA | 1 |
| Maleev, GV | 1 |
| Dubrovskaya, ES | 1 |
| Goreva, TV | 1 |
| Epishina, TA | 1 |
| Zamoyski, VL | 1 |
| Makhaeva, GF | 1 |
| Fisenko, VP | 1 |
| Veselov, IM | 1 |
| Vinogradova, DV | 1 |
| Bachurin, SO | 1 |
| Zhang, D | 1 |
| Geng, H | 1 |
| Cao, L | 1 |
| Li, W | 1 |
| Mazibuko, Z | 1 |
| Indermun, S | 1 |
| Govender, M | 1 |
| Kumar, P | 1 |
| Du Toit, LC | 1 |
| Choonara, YE | 1 |
| Modi, G | 1 |
| Naidoo, D | 1 |
| Pillay, V | 1 |
| Iwasaki, Y | 1 |
| Iguchi, H | 1 |
| Ichikawa, Y | 1 |
| Igarashi, O | 1 |
| Kawabe, S | 1 |
| Kiyozuka, T | 1 |
| Maruyama, M | 1 |
| Ikeda, K | 1 |
| Fujioka, T | 1 |
| Munsat, TL | 1 |
| Easterday, CS | 1 |
| Levy, S | 1 |
| Wolff, SM | 1 |
| Hiatt, R | 1 |
| Norris, FH | 1 |
| Brait, K | 1 |
| Fahn, S | 1 |
| Schwarz, GA | 1 |
1 trial available for amantadine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Amantadine and guanidine are ineffective in ALS.
Topics: Amantadine; Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Double-Blind Method; Guanidines | 1981 |
6 other studies available for amantadine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments.
Topics: Adamantane; Amantadine; Amyotrophic Lateral Sclerosis; Edaravone; Humans; Neuroprotective Agents; Ri | 2023 |
Clinical and Electrophysiological Features of Chronic Motor Axonal Neuropathy.
Topics: Amantadine; Amyotrophic Lateral Sclerosis; Electrophysiological Phenomena; Humans; Motor Neurons; Mu | 2022 |
Targeted Delivery of Amantadine-loaded Methacrylate Nanosphere-ligands for the Potential Treatment of Amyotrophic Lateral Sclerosis.
Topics: Amantadine; Amyotrophic Lateral Sclerosis; Animals; Antiparkinson Agents; Cells, Cultured; Drug Deli | 2018 |
Fatigue and depression are associated with poor quality of life in ALS.
Topics: Adaptation, Psychological; Amantadine; Amyotrophic Lateral Sclerosis; Caregivers; Cross-Sectional St | 2003 |
Amantadine in Jakob-Creutzfeldt disease.
Topics: Amantadine; Amyotrophic Lateral Sclerosis; Central Nervous System Diseases; Creutzfeldt-Jakob Syndro | 1972 |
Sporadic and familial parkinsonism and motor neuron disease.
Topics: Aged; Amantadine; Amyotrophic Lateral Sclerosis; Cerebellar Diseases; Corpus Striatum; Dihydroxyphen | 1973 |